Tocilizumab + Placebo

Phase 3Active

1 views this week 0 watching⚡ Active

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Giant Cell Arteritis

Conditions

Giant Cell Arteritis, Neurovascular Disorder

Trial Timeline

Sep 24, 2021 → Aug 13, 2025

NCT ID

NCT04888221

About Tocilizumab + Placebo

Tocilizumab + Placebo is a phase 3 stage product being developed by Roche for Giant Cell Arteritis. The current trial status is active. This product is registered under clinical trial identifier NCT04888221. Target conditions include Giant Cell Arteritis, Neurovascular Disorder.

What happened to similar drugs?

5 of 13 similar drugs in Giant Cell Arteritis were approved

Approved (5) Terminated (3) Active (6)

🔄PexidartinibDaiichi SankyoPhase 3

✅PexidartinibDaiichi SankyoApproved

🔄Upadacitinib + Corticosteroid (CS)AbbViePhase 3

🔄Secukinumab 300 mg, s.c. + Placebo to match Secukinumab, s.c.NovartisPhase 3

🔄Secukinumab 300 mg + Secukinumab 150 mgNovartisPhase 3

✅Tocilizumab + PrednisoneRocheApproved

🔄TocilizumabRochePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04888221	Phase 3	Active	Sep 24, 2021	Aug 13, 2025	Giant Cell Arteritis
NCT02908217	Phase 3	Completed	Feb 15, 2017	Nov 12, 2020	Polymyalgia Rheumatica
NCT01209689	Phase 3	Terminated	Oct 1, 2010	Dec 1, 2011	Spondylitis, Ankylosing
NCT01209702	Phase 3	Terminated	Sep 1, 2010	Dec 1, 2011	Spondylitis, Ankylosing
NCT00988221	Phase 3	Completed	Nov 30, 2009	Jan 28, 2013	Juvenile Idiopathic Arthritis

Competing Products

20 competing products in Giant Cell Arteritis

See all competitors

Product	Company	Stage	Hype Score
prednisone	Kiniksa Pharmaceuticals	Phase 2	29
Pexidartinib	Daiichi Sankyo	Phase 2	39
Pexidartinib	Daiichi Sankyo	Phase 3	44
Pexidartinib	Daiichi Sankyo	Approved	43
Baricitinib	Eli Lilly	Phase 2	35
Upadacitinib + Corticosteroid (CS)	AbbVie	Phase 3	40
dovitinib	Novartis	Phase 2	35
Secukinumab 300 mg, s.c. + Placebo to match Secukinumab, s.c.	Novartis	Phase 3	40
Secukinumab 300 mg, s.c. + Prednisolone + Placebo	Novartis	Phase 2	35
Secukinumab	Novartis	Phase 1	29
Secukinumab 300 mg + Secukinumab 150 mg	Novartis	Phase 3	40
Tocilizumab + Prednisone	Roche	Approved	43
Tocilizumab	Roche	Phase 3	40
Tocilizumab	Roche	Phase 1	29
Valganciclovir	Roche	Approved	35
Tocilizumab + Prednisone + Tocilizumab Placebo + Prednisone Placebo + Corticosteroids + Methotrexate	Roche	Phase 3	40
Tocilizumab + Glucocorticoids (GCs) + Placebo + Glucocorticoids (GCs)	Roche	Phase 2	35
tocilizumab and IV steroids combination	Roche	Phase 2	31
Denosumab	Amgen	Approved	43
Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]	Amgen	Phase 2	27